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ABSTRACT 
Carboplatin/taxane combination is first-line therapy for ovarian cancer. However, patients can encounter treatment delays, impaired 
quality of life, even death because of chemotherapy induced gastrointestinal (GI) toxicity. A candidate gene study was conducted to 
assess potential association of genetic variants with GI toxicity in 808 patients who received carboplatin/taxane in the Scottish 
Randomized Trial in Ovarian Cancer 1 (SCOTROC1). Patients were randomized into discovery and validation cohorts consisting of 
404 patients each. Clinical covariates and genetic variants associated with grade III/IV GI toxicity in discovery cohort were evaluated 
in replication cohort. Chemotherapy-induced GI toxicity was significantly associated with 7 SNPs in the ATP7B, GSR, VEGFA and 
SCN10A genes. Patients with risk genotypes were at 1.53 to 18.01 higher odds to develop carboplatin/taxane-induced GI toxicity 
(p<0.01). Variants in the VEGF gene were marginally associated with survival time. Our data provides potential targets for 
modulation/inhibition of GI toxicity in ovarian cancer patients. 
INTRODUCTION 
In United States, 21,980 new cases and 14,270 deaths of ovarian cancer were reported in 2014 according to the most recent survey by 
the American Cancer Society.1 It ranks fifth as the cause of cancer death in women and over 2 billion dollars are spent every year in 
the U.S. on its treatment.2 In combination with surgical cytoreduction, platinum (cisplatin or carboplatin) based chemotherapy in 
combination with a taxane agent (paclitaxel or docetaxel) is a standard treatment for ovarian cancer.3, 4 Despite the therapeutic impact 
of platinum in conjunction with taxane agents in the management of ovarian cancer, 20-30% of patients will face grade III/IV 
peripheral neuropathy, 30-40% grade IV neutropenia and 20% grade III/IV gastro-intestinal (GI) toxicity.5 Carboplatin/taxane-induced 
mucositis, diarrhea and vomiting represent a major GI toxicity that patients encountered in the SCOTROC1 trial, which recruited 1077 
ovarian cancer patients to treatment with either docetaxel–carboplatin or paclitaxel–carboplatin.6 Acute GI toxicity represents a 
substantial negative impact on patients’ quality of life.7 However, there are no genetic markers that have been shown to be associated 
with a higher risk of gastrointestinal toxicity after carboplatin/taxane therapy.   
 In this study, we investigated 1261 selected polymorphisms with described functional effects in 60 genes to identify any 
genetic variants associated with carboplatin/taxane-induced GI toxicities in ovarian cancer patients. The inclusion criteria of these 
genes were described previously.8 The findings of this study provide new biologic insights and potential predictive factors for risk of 
GI toxicity in ovarian cancer patients receiving carboplatin/taxane-based chemotherapy.  
 
 
METHODS 
Patients. A randomized phase III study, SCOTROC 1, recruited 1077 ovarian cancer patients to treatment with docetaxel–carboplatin 
(n=539) or with paclitaxel–carboplatin (n=538).6 Of the 1077 patient samples, 880 samples had germline DNA of sufficient quality for 
gene chip analysis.8 The GI-toxicity including mucositis, vomiting, and diarrhea was documented using the National Cancer Institute 
Common Toxicity Criteria (NCI–CTC, version 2.0). Written informed consent was collected from all patients. Details of SCOTROC1 
trial, patients’ demographic characteristics and clinical assessments were described previously.6 Clincal characteristics are displayed in 
Table 1. 
Genotyping. A total of 60 candidate genes (Supplemental table 1) with 1536 SNPs were genotyped with an Illumina GoldenGate 
custom SNP array (Illumina, San Diego, CA) (Supplemental table 2a) and an additional 33 SNPs not suitable for the Illumina assay 
were genotyped using pyrosequencing (Biotage, Uppsala, Sweden) (Supplemental table 2b). Specific genotyping methods were 
described previously.8 
Quality Control. To ensure high genotyping quality, only SNPs with greater than 90% efficiency for all patients were included in the 
analysis.  Of the 1569 SNPs genotyped, 1303 SNPs passed standards of genotyping efficiency. Of the 1303 SNPs, we evaluated 
potential deviations from Hardy-Weinberg proportions9 using a Chi-square test of association with a Bonferroni multiple testing 
correction for the significance cutoff.  A total of 42 SNPs showed significant deviations (after multiple testing correction) and were 
removed from the subsequent analysis (for a total of 1261 SNPs evaluated).  Principle Components Analysis (PCA) was performed on 
the remaining SNPs to evaluate potential population substructure. As expected given the self-reported ethnicity in the current cohort, 
no substructure was observed (data strongly grouped into a single cluster, and eigenvalues from the first three components were not 
significantly related to toxicity, data not shown). Additionally, only patients with an observed grade of GI toxicity and greater than 
90% complete observations for all SNPs were included in the association analysis. 880 patient samples were initially available, and 
808 passed completeness standard filters. The patients were randomly assigned into test/discovery and replication/validation cohorts, 
stratified by case/control status to achieve equal numbers of cases in both sets: 71 cases (grade III/IV GI toxicity) and 333 controls 
(grade I/II GI toxicity) were included in the testing/discovery set, and 72 cases and 332 controls in the validation/replication set 
(Figure 1).  
Data Analysis. The aim of this study was to discover variants associated with chemotherapy induced GI toxicity rather than building a 
predictive model, with an emphasis on whether genetic information had influence after accounting for clinical variables. Clinical 
covariates and genetic variants significantly associated with grade III/IV GI toxicity in the first discovery cohort were evaluated in the 
second replication cohort. Important clinical covariates significantly associated with the response were selected with step-wise logistic 
regression to minimize AIC (Akaike’s Information Criteria).10; selected covariates included pre-treatment ECOG performance status, 
CA125 response, treatment arm, survival status, and first cycle at which neuropathy was experienced. Single-SNP analyses including 
important clinical covariates were performed using logistic regression in order to test for association of each SNP with toxicity; no 
genetic model of inheritance was assumed, and a genotypic model was used that included dummy variables for the SNP genotypes. 
SNPs with nominal p-values less than 0.05 were evaluated in the validation set. This two-stage analysis identifies SNPs that replicate 
in independent data, which reduces possible false positive associations. Across both independent replication sets, we calculate a joint 
p-value and ascribe statistical significance using permutation testing (repeating the entire variable selection and two-stage approach). 
A corrected p-value was obtained from this permutation test that can be compared to the usual 5% significance level to account for 
multiple testing and our two-stage design. 
To further reduce potential false positive findings, only the SNPs that met these strict criteria and also were consistent in 
direction of the risk effect for each genotype (positive vs. negative estimated odds ratio) were considered true replications. 
Additionally, to further examine the cumulative effect of genetic risk variants, we constructed a genetic risk score equal to the number 
of independent risk genotypes possessed by each individual, based on the four independent genetic signals (risk genotypes at SNPs in 
high LD were counted only once). Therefore the genetic risk score could take on values of 0, 1, 2, 3, or 4; because only one individual 
possessed 4 risk genotypes, the genetic risk score was modeled as an ordinal variable with categories 0, 1, 2, and 3+. This score was 
examined as an exploratory data analysis, and does not represent a predictive model; the predictive ability of this score should be 
evaluated in an independent cohort. 
We also investigated whether the SNPs significantly associated with GI toxicity were also associated with either overall 
survival or progression free survival time after controlling for important clinical covariates (ECOG performance status, CA125 
response, FIGO stage, histology, presence of neuropathy, bulk of residual disease, and clinical response) using a Cox Proportional 
Hazards model. All data analysis was performed in the freely-available R-software (http://www.r-project.org/).11 
 
RESULTS 
SNPs associated with grade III/IV GI toxicity 
The regression modeling of the clinical data identified the following variables as covariates for further analysis of the risk of 
developing grade III/IV GI toxicity: treatment arm, first cycle of grade 2 neuropathy, CA125 response, overall survival, and ECOG 
status.  From the 1261 SNPs that passed quality control standards, 81 SNPs were significant in the test set at the p<0.05 level. Of those 
significant in the test set, 11 were also significant in the validation set.  Seven of these SNPs passed further assessment for direction of 
effect and a genotypic model was selected as the most likely genetic model for all SNPs (Figure 1).  These seven SNPs reside in or 
near four genes: ATP7B, GSR, VEGFA, and SCN10A (Table 2).  The odds of developing platinum/taxane-induced GI toxicity in 
patients with risk genotypes ranged from 1.53 to 18.01 times for each risk SNP (corrected P<0.05; Table 2). For each SNP, genotype 
counts by GI toxicity status are displayed for each cohort (Table 3).  The independence of each significant SNP from other SNP 
signals was assessed by evaluating linkage disequilibrium (LD) between the markers (quantified as R2 values) (Shown in Table 4). 
Rs1061472 and rs1801249 are both in ATP7B and are in strong LD (R2=91.78%) and rs6900017, rs879825 and rs9369421 are all in 
VEGFA and are in strong LD (Table 4); therefore these five SNPs represent only two independent genetic signals.  
Genetic Risk Score Analysis 
After calculating a risk genotype composite score for each individual (equal to the number of independent risk genotypes that 
individual carries), a strong association between the number of risk genotypes and GI toxicity was observed (Figure 2A). The number 
of risk genotypes was associated with a multiplicative increase in the odds of developing GI toxicity, with the odds of developing GI 
toxicity estimated to increase by an average of 1.89 for every subsequent risk genotype (p=1.62E-7), although this is only marginally 
significant after permutation correction (p=0.056).  Patients with a composite score of 2 had an estimated odds ratio for GI toxicity of 
3.56 (2.21-5.72) compared to individuals with a composite score of 0. The number and percentage of patients in each genetic risk 
score category by GI toxicity/no toxicity status are presented in Table 5, along with the model odds ratios.  
Survival time analysis 
Patients with a high risk genotype score (2-3+ risk genotypes) had the same progression free survival (p=0.98) and overall survival 
(p=0.90) as patients with the lower risk composite score (0-1 risk genotypes) (Figure 2B and 2C, respectively).  Additionally, Cox 
proportional hazards analysis for both survival time and progression-free survival for each individual genotype indicate no association 
with progression-free or overall survival.  The only SNP in association with patient’s survival time is VEGFA rs9369421, where 
genotype GG is associated with high risk of GI toxicity (Figure 3). However, the G allele is associated with increased survival; the 
hazard, or risk of death, for patients with genotype AA (n=685) is 1.58 times higher than patients with either AG or GG genotype 
(n=120) (p=0.012). 
 
DISCUSSION 
In this study, seven SNPs from four genes (ATP7B, GSR, VEGFA, and SCN10A) were found to be associated with 
platinum/taxane-induced grade III/IV GI toxicity in ovarian cancer patients. The odds for a patient to develop severe GI toxicity are 18 
times higher in VEGFA rs879825 GG carriers than A allele carriers. To date, the most promising association between gene variants 
and platinum/taxane-induced grade III/IV GI toxicity in ovarian cancer patients was reported in 118 Korean patients that revealed a 
strong risk with carriage of the ABCB1 2677 T or A allele (adjusted odds ratio, 9.74; 95% CI, 1.59–15.85).12 However, no significant 
association was found with this variant in our previous small-scale study13 and was not validated in this study either. Inconsistent 
results of ABCB1 2677G>T/A pharmacogenetics were seen in breast cancer, non-small cell lung cancer and prostate cancer patients 
receiving platinum/taxane regarding patients’ survival time as well.14-16 ABCB1 encodes a cross membrane protein named P-
glycoprotein (P-gp) that effluxes a wide range of structurally diverse substrates including xenobiotics and endogenous compounds.17 
Substrates can interact with chemotherapy agents which may mask the impact of ABCB1 variants on the pharmacokinetics of drugs,18 
especially in cancer patients that multiple drugs are administrated concomitantly. This could be a cause of inconsistent findings of 
ABCB1 pharmacogenetics in different cancer patients.  
 Deeken and his colleagues assessed 1256 SNPs in 170 drug metabolism and disposition genes in 74 prostate cancer patients 
who received either docetaxel and thalidomide, or docetaxel alone.19 Twenty three genes were common between DMET 1.0 and the 
123 genes assessed in our study (Supplemental table 3). ATP7A and CYP2D6 genes were correlated with docetaxel related toxicity in 
Deeken’s study (p<0.01). However, this result was not replicated in either our previous small-scale study or the current, expanded 
study. ATP7B gene was identified as a significant marker for carboplatin/taxane-related GI toxicities (p<0.01). This effect was not 
seen in Deeken’s study.19  Different combinations of chemotherapy may mask the genetic effect on drug response and toxicity. 
Moreover, the same gene or variants may also play a different role in different cancers while the same drug treatment is applied.  
The findings of this study provides novel genes that may be correlated with platinum/taxane based therapy, although it remains 
unclear given that few reports have disclosed an important role of any of the above genes in the metabolism or disposition of either 
agent. Moreover, the gene variations that are known to be involved in detoxification, disposition and response to carboplatin/taxane, 
including the 7 genes overlapped in our previous study, were not associated with either toxicity or survival time. Although these genes 
may play a role in platinum/taxane metabolism pathways directly or indirectly, we can only speculate the mechanism of gene-drug 
interactions. For instance, the function of rs9825762 of SCN10A gene was unclear but the rs3594 of glutathione reductase, GSR, gene 
was associated with oxidative stress status of children infected by malaria, which suggested a potential function of this variant. 20 The 
ATP7B (ATPase, Cu++ transporting, beta polypeptide) gene encodes a protein called copper-transporting ATPase 2. This protein is 
found primarily in the liver and plays a role in transporting copper from the liver to other organs. It is also important for the 
elimination of excess copper from the body through bile. 21 ATP7B gene mutations may cause copper accumulation in tissues. As a 
result, toxic level of copper could impair the lining of the gastrointestinal tract and trigger nausea and vomiting while chemotherapy 
was applied. Molecular genetic testing for ATP7B mutations is available in clinic, which is applied for diagnosis/prediction of a 
disease caused by ATP7B mutations, Wilson's disease.22 A study in pre-school kids found that rs6900017 of VEGFA gene was 
associated with their lung function at school age but not at birth which suggested a potential function of VEGFA variants in lung 
development. 23 Although no studies of the function of rs879825 and rs9369421 so far, they are in high linkage disequilibrium with 
rs6900017 as we found in our study. VEGFA also has been identified as the primary tumor angiogenesis factor and targeted by several 
newly developed agents for patients with metastatic carcinoma. However, these novel VEGF targeting agents including bevacizumab, 
sorafenib, sunitinib, brivanib and cilengitide have had only modest effect on human cancers.24 In combination with standard 
chemotherapy, carboplatin–paclitaxel, and bevacizumab moderately improved progression free survival time in ovarian cancer 
patients according to two randomized phase III studies, GOG218 and ICON7.25, 26 Additionally, VEGFA gene variants were found to 
be related to the therapeutic outcome of oxaliplatin based chemotherapy in metastatic colorectal cancer patients.27 However, these 
variants were not associated with the GI toxicity of carboplatin based chemotherapy in ovarian cancer patients. In this study, three 
variants of VEGFA gene were found highly correlated with chemotherapy induced GI toxicity which indicated a critical role of 
VEGFA in ovarian cancer patients who received a standard chemotherapy. 
In summary, this study is the first step in defining a pharmacogenetics model for platinum/taxane-induced GI toxicity in 
ovarian cancer patients. Seven SNPs from four genes increased the risk of developing platinum/taxane-induced grade 3-4 GI toxicity, 
whereas VEGFA gene was associated with patients’ survival time. Our data suggests new genetic markers associated with 
platinum/taxane GI toxicity in ovarian cancer patients and the risk may vary between populations because the minor allele frequency 
of these risk variants are quite different in Caucasian, Asian and African populations. These genetic markers provide potential targets 
to modulate/inhibit GI toxicity in ovarian cancer patients. Further studies are required to validate these risk factors from in vitro 
models to independent clinic trials in multiple ethnic groups to clarify the potential role they might play in predicting chemotherapy 
induced GI toxicity and to evaluate the value of these risk variants as therapeutic markers.  
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Table 1: Clinical characteristics by cohort. 
 
  Replication Set 
(N=404) 
Discovery Set 
(N=404) 
Total (N=808) 
Variable Level N % N % N % 
FIGO stage IC 27 6.7% 25 6.2% 52 6.4% 
 II 57 14.1% 41 10.1% 98 12.1% 
 III 257 63.6% 281 69.6% 538 66.6% 
 IV 63 15.6% 57 14.1% 120 14.9% 
Tumor grade Well differentiated 27 6.7% 30 7.4% 57 7.1% 
 Moderate 103 25.5% 108 26.7% 211 26.1% 
 Poor/undifferentiated 222 55.0% 221 54.7% 443 54.8% 
 Unknown 52 12.9% 45 11.1% 97 12.0% 
ECOG status 0 142 35.1% 126 31.2% 268 33.2% 
 1 211 52.2% 215 53.2% 426 52.7% 
 2 51 12.6% 63 15.6% 114 14.1% 
CA125 response No response 59 14.6% 71 17.6% 130 16.1% 
 Response 213 52.7% 211 52.2% 424 52.5% 
 Not evaluated 132 32.7% 122 30.2% 254 31.4% 
Treatment Paclitaxel/Carboplatin 196 48.5% 204 50.5% 400 49.5% 
 Docetaxel/Carboplatin 208 51.5% 200 49.5% 408 50.5% 
Worst grade of GI toxicity 0 19 4.7% 18 4.5% 37 4.6% 
 1 105 26.0% 107 26.5% 212 26.2% 
 2 208 51.5% 208 51.5% 416 51.5% 
 3 66 16.3% 64 15.8% 130 16.1% 
 4 6 1.5% 7 1.7% 13 1.6% 
Worst grade of 
neuropathy 
0 143 35.4% 142 35.1% 285 35.3% 
 1 169 41.8% 172 42.6% 341 42.2% 
 2 64 15.8% 71 17.6% 135 16.7% 
 3 26 6.4% 18 4.5% 44 5.4% 
 4 2 0.5% 1 0.2% 3 0.4% 
First cycle of grade 2 
neuropathy 
1 16 4.0% 9 2.2% 25 3.1% 
 2 21 5.2% 16 4.0% 37 4.6% 
 3 37 9.2% 21 5.2% 58 7.2% 
 4 27 6.7% 29 7.2% 56 6.9% 
 5 21 5.2% 22 5.4% 43 5.3% 
 Censored 282 69.8% 307 76.0% 589 72.9% 
Survival status Alive 252 62.4% 262 64.9% 514 63.6% 
 Dead 152 37.6% 142 35.1% 294 36.4% 
Median survival time (months) 20.05  20.30  20.24  
 
 
Table 2.  SNPs significantly associated with significant gastro-intestinal toxicity in the discovery and replication cohorts. Analyses are 
adjusted for ECOG performance status, CA125 response, treatment arm, survival status, and first cycle at which neuropathy was 
experienced. 
 
SNP Gene Polymorp
hism 
P-value 
Discovery 
Set 
(N=404) 
P-value 
Replicatio
n Set 
(N=404) 
Joint 
P-value 
Corrected 
P-Value 
(compare 
to 0.05) 
Odds Ratio 
(N=808) 
95% CI 
(N=808) 
Risk 
Genotype 
rs1061472 ATP7B A->G 0.004 0.031 
1.22E-
04 
0.00111 1.70 (1.02, 2.84) AA 
rs1801249 ATP7B A->G 0.003 0.032 
8.64E-
05 
0.00081 1.53 (0.93, 2.51) AA 
rs3594 GSR A->C 0.035 0.030 
1.05E-
03 
0.00848 2.83 (1.45, 5.52) CC 
rs6900017 VEGFA A->G 0.037 0.040 
1.47E-
03 
0.01162 9.97 (1.85, 53.72) AA 
rs879825 VEGFA A->G 0.036 0.014 
4.97E-
04 
0.00417 18.01 (2.78, 116.56) GG 
rs9369421 VEGFA A->G 0.040 0.037 
1.47E-
03 
0.01162 9.91 (1.83, 53.52) GG 
rs9825762 SCN10
A 
A->G 
0.018 0.022 
3.90E-
04 
0.00335 1.90 (0.76, 4.77) AA 
 
 
 
  
 
 
 
 
 
Table 3. Genotype counts by GI toxicity status for each cohort. 
  
Discovery Set Validation Set Total 
SNP Genotype 
Grade 
I/II 
Grade 
III/IV 
Grade 
I/II 
Grade 
III/IV 
Grade 
I/II 
Grade 
III/IV 
rs1061472 AA 54 19 58 21 112 40 
rs1061472 AG 177 31 166 24 343 55 
rs1061472 GG 93 19 97 24 190 43 
rs1801249 AA 52 18 57 20 109 38 
rs1801249 AG 172 28 167 23 339 51 
rs1801249 GG 106 24 105 28 211 52 
rs3594 AA 58 7 56 5 114 12 
rs3594 AC 152 27 138 32 290 59 
rs3594 CC 114 34 132 35 246 69 
rs6900017 AA 2 2 1 1 3 3 
rs6900017 AG 41 7 48 13 89 20 
rs6900017 GG 286 62 283 58 569 120 
rs879825 AA 298 64 293 61 591 125 
rs879825 AG 30 4 37 9 67 13 
rs879825 GG 1 2 1 1 2 3 
rs9369421 AA 287 62 277 59 564 121 
rs9369421 AG 44 6 52 12 96 18 
rs9369421 GG 2 2 1 1 3 3 
rs9825762 AA 189 53 196 53 385 106 
rs9825762 AG 124 16 117 15 241 31 
rs9825762 GG 20 2 17 4 37 6 
 
Table 4. LD correlation matrix (R2) for the seven SNPs associated with significant gastro-intestinal toxicity 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Frequencies (percentages) of cases and controls in each genetic risk category. 
 
Risk Score 0 1 2 3+ Total 
Cases 15 (10%) 54 (38%) 58 (41%) 16 (11%) 143 
Controls 148 (22%) 309 (46%) 184 (28%) 24 (4%) 665 
Total 163 (20%) 363 (45%) 242 (30%) 40 (5%) 808 
Model Odds 
Ratio 
1.0 1.89 3.56 6.71  
 
  rs1061472 rs1801249 rs3594 rs6900017 rs879825 rs9369421 rs9825762 
Chr.13 rs1061472 1.0000 0.9178 0.0003 0.0045 0.0058 0.0046 0.0003 
Chr.13 rs1801249 0.9178 1.0000 0.0000 0.0051 0.0060 0.0052 0.0002 
Chr.8 rs3594 0.0003 0.0000 1.0000 0.0000 0.0001 0.0000 0.0003 
Chr.6 rs6900017 0.0045 0.0051 0.0000 1.0000 0.7420 0.9706 0.0001 
Chr.6 rs879825 0.0058 0.0060 0.0001 0.7420 1.0000 0.7724 0.0001 
Chr.6 rs9369421 0.0046 0.0052 0.0000 0.9706 0.7724 1.0000 0.0000 
Chr.3 rs9825762 0.0003 0.0002 0.0003 0.0001 0.0001 0.0000 1.0000 
Figure 1. Workflow of the data analysis, with processing of the samples shown in gray, and the workflow related to the SNPs shown 
in black. 
 Figure2. (A) Proportion of ovarian cancer cases experiencing GI toxicity by number of risk genotypes. (B) Progression Free Survival 
Time by number of risk genotypes. (C) Overall Survival Time by number of risk genotypes. 
 
 
Figure 3.  Survival time by rs9369421 genotype. (Kaplan-Meier survival curve, log rank analysis) 
 
 
 
Supplementary table 1:  123 genes genotyped in this study 
Detoxification Apoptosis or cell signal DNA repair or regulation Disposition Neuropathies 
AKR1B1 AR ERCC1 ABCA4 ANK3 
ALDH1A1 BAX ERCC2 ABCB1 DST 
CYP1B1 BCL2 ERCC5 ABCC1 INA 
CYP2C19 BCL2L1 ERCC6 ABCC2 MAP4 
CYP2C8 BIRC2 GARS ABCC5 MAPK1 
CYP2C9 BIRC4 MGMT ABCG2 MAPT 
CYP2D6 CAMK2B MLH1 ATP7A MFN2 
GPX1 CCND1 MTHFR ATP7B MPZ 
GPX2 CD40LG PPARA CACNA2D1 MT1A 
GPX4 CD8A PPARG CFTR MT1F 
GSR DCT RB1 GJB1 NEFH 
GSS DNM2 RBM17 SCN10A NEFL 
GSTA1 EGR2 RRM2 SCN1A NEFM 
GSTM1 EPHA2 TLR4 SCN2A NFKB1 
GSTP1 EPO VDR SCN4A NGFB 
PON1 ESR1 XRCC1 SCN7A NGFR 
PON2 GDAP1  SCN8A NTRK1 
PTGS2 HMGB1  SCN9A OPRK1 
SOD1 HSPA5  SCNN1A OPRM1 
TPMT IL6  SLC11A1 PMP22 
UGT1A1 OPRM1  SLC15A2 PNPLA6 
XDH PPP4R1  SLC19A1 PRX 
 PPP4R2  SLC22A1 SOX10 
 PRKCB1  SLC22A16 SPTAN1 
 PRR13  SLC22A2 TRPV1 
 RAB7  SLC31A1 TRPV5 
 RAMP1  SLC40A1 TRPV6 
 TP53  TAP1  
 TUBB3    
 VEGF    
 YARS    
Supplemental Table 2:  All SNPs genotyped including a. 1536 SNPs on the Illumina GoldenGate custom SNP array and b. 33 SNPs 
genotyped by pyrosequencing.   
 
a. SNPs on Illumina GoldenGate custom SNP array 
rs3213245 rs4417063 rs885479 rs304729 rs6467897 rs2302236 
rs11168286 rs11829863 rs12465675 rs3810366 rs11568820 rs10994148 
rs5912559 rs13025009 rs4987786 rs6675934 rs2296147 rs4784701 
rs6928818 rs12779378 rs7975319 rs3900008 rs6058391 rs8176036 
rs4760650 rs6795970 rs11688164 rs7191944 rs10267099 rs1860545 
rs2893389 rs6763876 rs12320663 rs877611 rs304731 rs4558416 
rs2228478 rs3746166 rs3213829 rs74915 rs3745202 rs4728502 
rs10445337 rs1483000 rs9323457 rs3212363 rs2316776 rs2229107 
rs2069829 rs10994162 rs7132324 rs3757985 rs10404348 rs2214102 
rs4987849 rs1016860 rs9524489 rs4941716 rs4149578 rs1157511 
rs10175267 rs10821662 rs10858075 rs4623700 rs7965281 rs2393602 
rs10808299 rs10821683 rs739837 rs10509117 rs7139166 rs11574077 
rs3213246 rs11588779 rs4395073 rs2239622 rs10509119 rs2074447 
rs3741707 rs11700037 rs2074452 rs8081989 rs2299185 rs4253002 
rs4732449 rs11988344 rs2887140 rs10954673 rs1529668 rs17803819 
rs3212368 rs13041792 rs7958704 rs1467966 rs3754963 rs4743 
rs2893388 rs1381547 rs11971283 rs17564983 rs7100448 rs4150386 
rs11720058 rs1381548 rs1805005 rs10486948 rs762562 rs2077360 
rs2316777 rs1564483 rs12632942 rs2979687 rs1827208 rs10761450 
rs2010963 rs1610095 rs11466103 rs2976427 rs4150383 rs161383 
rs4252418 rs1799787 rs13254844 rs2166772 rs3212346 rs17651549 
rs1799788 rs2121371 rs744389 rs17634022 rs9524500 rs4148150 
rs12664104 rs2126152 rs2074445 rs12423042 rs2005132 rs7232082 
rs11988346 rs2156192 rs7965397 rs4858887 rs4252499 rs929351 
rs3741708 rs2228527 rs2229920 rs4839435 rs2270836 rs161365 
rs2258689 rs2295283 rs10416031 rs10776797 rs11900439 rs38559 
rs4252417 rs3114018 rs7136534 rs545331 rs4987859 rs10994171 
rs13016251 rs3746165 rs11168290 rs10776798 rs7630989 rs6329 
rs3109823 rs4253211 rs12354956 rs2471736 rs928169 rs2970504 
rs11720061 rs490317 rs4146585 rs11880613 rs4135301 rs38557 
rs2316780 rs4987752 rs460716 rs3744683 rs11672096 rs9668931 
rs12048019 rs562859 rs3801739 rs2043332 rs12720464 rs924469 
rs675026 rs6678788 rs7921 rs3213244 rs7627568 rs3785930 
rs5912558 rs699947 rs11659758 rs9692165 rs10849446 rs4076018 
rs7965274 rs873458 rs1948431 rs9915741 rs1990071 rs2671642 
rs10821677 rs1800795 rs3212345 rs7374804 rs3759324 rs2239179 
rs10821659 rs11614164 rs1540339 rs11466086 rs12944357 rs4252412 
rs7965266 rs2298881 rs4150324 rs4076737 rs2336219 rs4253003 
rs2893823 rs6087656 rs17563965 rs1012018 rs161375 rs8000418 
rs6809264 rs7989652 rs10158276 rs12760036 rs4474385 rs17650901 
rs10175360 rs4236480 rs4479290 rs268674 rs2025097 rs8079120 
rs2393576 rs12763974 rs11658700 rs4790520 rs11672431 rs10954670 
rs11466087 rs17791817 rs4334089 rs8177146 rs11671653 rs238416 
rs2278444 rs2435204 rs4858881 rs268662 rs939336 rs11568305 
rs12779035 rs1126112 rs11574026 rs16949859 rs9301959 rs4761986 
rs4987847 rs10776800 rs12402406 rs9967700 rs2070720 rs10994160 
rs11466088 rs7224541 rs10761452 rs1998876 rs3766744 rs2299169 
rs2336384 rs231017 rs9895612 rs230938 rs4252535 rs17773227 
rs6791171 rs9922409 rs2013775 rs4987665 rs6499850 rs7068231 
rs7540561 rs12150576 rs38555 rs2393581 rs9524494 rs1052587 
rs13015709 rs4987855 rs12058002 rs3785931 rs7649970 rs2237526 
rs16914571 rs17184707 rs12232396 rs3213238 rs17033692 rs10876200 
rs4252357 rs9828268 rs599548 rs11712354 rs3805134 rs12302725 
rs4657015 rs13306558 rs6747673 rs4676593 rs1800100 rs17156246 
rs741071 rs3097112 rs7430439 rs2914879 rs10278483 rs2316782 
rs9563078 rs3847987 rs2075572 rs3025000 rs161381 rs2856813 
rs3890734 rs4870266 rs9827941 rs4987682 rs4773797 rs7588659 
rs4902343 rs16940799 rs6819279 rs2368020 rs6580842 rs2236055 
rs11816586 rs4941188 rs17830392 rs4253060 rs11971167 rs2853564 
rs12150460 rs7299460 rs4760658 rs879207 rs4148725 rs4150393 
rs3769943 rs10821666 rs35588 rs9900655 rs4712138 rs9827945 
rs4252372 rs10994198 rs8060203 rs12996930 rs10821660 rs12330440 
rs4253012 rs4994970 rs11466075 rs17650771 rs10994182 rs12957119 
rs11130152 rs2108373 rs1381109 rs6599250 rs3760239 rs10994174 
rs2094258 rs719452 rs2975180 rs6432894 rs4073129 rs3810031 
rs10509121 rs11574132 rs2239186 rs8080613 rs4987866 rs3791251 
rs16851332 rs17802184 rs6580643 rs10171225 rs11574124 rs4948254 
rs7651106 rs7900212 rs7305135 rs12581731 rs2141384 rs510587 
rs3745674 rs13447445 rs4252416 rs11924846 rs4987844 rs6599237 
rs767059 rs612020 rs17183814 rs1406274 rs6724623 rs3213266 
rs2281885 rs12457831 rs3786719 rs7428538 rs10237261 rs4252444 
rs4792893 rs3801705 rs17070861 rs2393577 rs179521 rs12357325 
rs10221276 rs1132776 rs10994189 rs9561561 rs610231 rs13006006 
rs540825 rs4148682 rs7068951 rs11168287 rs3025030 rs4149570 
rs12026714 rs7808770 rs6532049 rs11716467 rs4512905 rs585916 
rs4803817 rs5742912 rs10279911 rs10417071 rs557222 rs600120 
rs6591252 rs8077624 rs3798683 rs3744685 rs11466072 rs3024994 
rs7570585 rs4252484 rs268665 rs12961672 rs11466073 rs12497191 
rs9970214 rs11721285 rs11466106 rs13239493 rs11466162 rs1035050 
rs12946669 rs3025040 rs6088659 rs7638903 rs4760648 rs11982475 
rs17177522 rs3916874 rs12025459 rs10994180 rs892086 rs12023088 
rs3213282 rs1992294 rs8065080 rs11101137 rs9584233 rs4253200 
rs1827213 rs2709778 rs10439143 rs4899154 rs12490478 rs11466062 
rs12708963 rs2856811 rs13397210 rs6967334 rs2682562 rs12970840 
rs1483001 rs4948383 rs16832813 rs17036333 rs7272062 rs2299164 
rs3785880 rs10951271 rs2256507 rs11102916 rs10188577 rs2725245 
rs17769319 rs17207897 rs39742 rs8191005 rs4252435 rs10083198 
rs11574120 rs3759681 rs4150992 rs7372391 rs4792894 rs11102929 
rs3782723 rs3782478 rs915927 rs9825762 rs10857502 rs12203621 
rs735482 rs1799782 rs1078534 rs4516035 rs873601 rs3785380 
rs2239181 rs303803 rs1886087 rs7100478 rs9844644 rs1001362 
rs12205732 rs4804523 rs222740 rs7966983 rs10876202 rs11553502 
rs7580482 rs17749561 rs3819545 rs3097109 rs16852186 rs2316781 
rs12478318 rs268664 rs4431977 rs6722503 rs4987597 rs17649518 
rs2281793 rs16822821 rs2277501 rs12457371 rs3744937 rs3212369 
rs3757630 rs171140 rs2979681 rs1061003 rs11551042 rs13113161 
rs4335044 rs17030665 rs4253009 rs10783462 rs11878644 rs10761438 
rs2072325 rs12581281 rs6760593 rs16949864 rs161364 rs4253121 
rs4252381 rs2214106 rs11466084 rs17033622 rs2147362 rs17678294 
rs11152374 rs11881315 rs4948382 rs3760237 rs4987853 rs38545 
rs17706630 rs6912029 rs16949829 rs60637 rs2367914 rs12060354 
rs6923231 rs7544163 rs4252424 rs7247567 rs252853 rs224534 
rs7217945 rs17650579 rs9479756 rs9478506 rs1318345 rs2583118 
rs7563854 rs4948381 rs6802898 rs1138272 rs7230970 rs3801712 
rs6731591 rs12019609 rs10266993 rs10995317 rs1358533 rs1695 
rs12707486 rs4252402 rs1026825 rs11090819 rs1368234 rs1708403 
rs16940742 rs9646771 rs1028805 rs11152370 rs1380452 rs1709183 
rs17650417 rs9904290 rs1028806 rs11190297 rs1380454 rs1712517 
rs2069827 rs10994195 rs1040822 rs11407 rs1380459 rs17149854 
rs11644157 rs3744681 rs1041740 rs1143670 rs1381108 rs172559 
rs1993614 rs10733758 rs1042837 rs11596260 rs1381376 rs17262683 
rs2257212 rs4761830 rs10432782 rs11599164 rs1383596 rs174649 
rs4676595 rs7513144 rs1047768 rs11615 rs139873 rs17655 
rs8078212 rs10821668 rs1047769 rs1163081 rs139879 rs1799971 
rs9303523 rs1551683 rs10503077 rs11687273 rs139883 rs1799977 
rs2854496 rs7915375 rs10503078 rs1172384 rs139884 rs1800668 
rs11574027 rs8082597 rs10503079 rs11766273 rs139887 rs1800669 
rs17265047 rs1905248 rs1050351 rs11872991 rs139889 rs1801018 
rs9322445 rs6735176 rs1050745 rs11876772 rs139892 rs1801243 
rs9524493 rs4253055 rs1051298 rs11888208 rs1404045 rs1801244 
rs9524504 rs16914968 rs1051332 rs1191236 rs1406275 rs1801249 
rs4987595 rs10858072 rs1057373 rs11920521 rs1407995 rs1807999 
rs7308367 rs17649571 rs1059111 rs11965988 rs1415568 rs1810563 
rs8065469 rs4567277 rs1061472 rs11968575 rs1439791 rs1824549 
rs9637536 rs6599239 rs1064108 rs11978472 rs1457266 rs182637 
rs17650335 rs9369421 rs10740006 rs11986256 rs1459730 rs1834839 
rs12356776 rs10994190 rs10740011 rs11994760 rs1459731 rs1834840 
rs3782905 rs7086260 rs10740022 rs12009 rs1461193 rs1859541 
rs11168288 rs11168292 rs10761445 rs12058927 rs1461195 rs1859542 
rs2302898 rs17247184 rs10761473 rs1211152 rs1461202 rs1864325 
rs6746030 rs9641019 rs10776572 rs12210856 rs1462129 rs1881998 
rs12967026 rs6968468 rs10776799 rs12217983 rs1467967 rs1886049 
rs12253260 rs12119346 rs10786172 rs12355908 rs1467970 rs1886330 
rs17769186 rs4252537 rs10808298 rs12396249 rs1468402 rs1890951 
rs7615140 rs17125929 rs10817465 rs12457170 rs1471247 rs1893506 
rs10442682 rs2525046 rs10821663 rs12473643 rs1474868 rs1913474 
rs17070946 rs222738 rs10821688 rs12491593 rs1481031 rs1917799 
rs17759659 rs9526810 rs10821703 rs12545967 rs1481032 rs1918760 
rs7520839 rs10233444 rs10821704 rs12606418 rs1505 rs1919179 
rs2291957 rs11170558 rs10821708 rs12621853 rs1523519 rs1922076 
rs230911 rs1002149 rs10821709 rs12707484 rs1528488 rs1924608 
rs9815891 rs1002442 rs10821723 rs12778431 rs1531695 rs1924609 
rs2393595 rs1005230 rs10821747 rs12844215 rs1531697 rs1927907 
rs3213403 rs1005793 rs10829611 rs12844432 rs1540923 rs1934956 
rs6060129 rs1007722 rs10829619 rs12996382 rs1540979 rs1944419 
rs477292 rs10090060 rs10905806 rs13029092 rs1542578 rs1944420 
rs17309872 rs1010344 rs10930202 rs13181 rs1547651 rs1944423 
rs2236270 rs1011696 rs10945657 rs13193952 rs1554817 rs1947114 
rs8190893 rs10133054 rs10954664 rs1325611 rs1557044 rs1954134 
rs11813307 rs10133290 rs10954669 rs1340652 rs1579865 rs196858 
rs38556 rs1020853 rs10994199 rs1340655 rs161382 rs1972445 
rs603769 rs10218875 rs10994204 rs13421166 rs1617640 rs1977971 
rs1143672 rs10232351 rs10994250 rs13437608 rs162562 rs1981251 
rs3759333 rs10240637 rs10994257 rs1344229 rs16850426 rs1981434 
rs9990137 rs1024195 rs10994293 rs1350631 rs16851799 rs1982673 
rs11169883 rs1024196 rs10995314 rs135538 rs16852112 rs1982674 
rs1994251 rs2241540 rs2393625 rs303824 rs3793903 rs4320778 
rs1997625 rs224277 rs2518462 rs303828 rs3793936 rs4332358 
rs1998220 rs224285 rs252854 rs3087548 rs3802689 rs4333102 
rs2016073 rs224546 rs2529437 rs3092948 rs3806962 rs4384970 
rs2017362 rs2253409 rs25486 rs3134609 rs3808942 rs4410896 
rs2018836 rs2256327 rs25487 rs316032 rs3810831 rs4426541 
rs2028026 rs2268793 rs2551397 rs3181073 rs3811014 rs4429487 
rs2030404 rs2270459 rs2551399 rs319693 rs3816560 rs4443014 
rs2031002 rs2272381 rs2551715 rs3212948 rs3819437 rs4453709 
rs2031526 rs2273683 rs25648 rs3212986 rs3823010 rs4456611 
rs2031527 rs2273684 rs258651 rs3448 rs3825527 rs4480996 
rs2031529 rs2274359 rs2593529 rs3460 rs38564 rs4526262 
rs2046136 rs2277502 rs2622604 rs348472 rs3924001 rs4529705 
rs2051423 rs2279115 rs2644596 rs353138 rs3927911 rs4565713 
rs2058194 rs2279420 rs268666 rs353139 rs3935511 rs4597545 
rs2062010 rs2280961 rs268673 rs35597 rs399413 rs4611159 
rs2062011 rs2281547 rs2689283 rs3594 rs4073960 rs4626883 
rs206811 rs2281617 rs2700424 rs366732 rs4076194 rs4632359 
rs2068797 rs2281620 rs2712402 rs37067 rs4129395 rs4633936 
rs2070776 rs2282059 rs2737844 rs37074 rs4131162 rs4635033 
rs2073337 rs2282937 rs2813544 rs37134 rs4131826 rs4642534 
rs2103277 rs2287499 rs2833477 rs37135 rs4147263 rs4657016 
rs2104353 rs2288358 rs2842941 rs3731863 rs4150276 rs4667485 
rs2114104 rs2288359 rs2849377 rs3739345 rs4150339 rs4667808 
rs2114760 rs2293537 rs2849380 rs3742305 rs4150355 rs4674301 
rs2116658 rs2293567 rs2849381 rs3742599 rs42056 rs4711312 
rs2141615 rs2295281 rs2850760 rs3748895 rs4236479 rs4728709 
rs2147363 rs2295676 rs2850761 rs3750332 rs4236481 rs4732420 
rs2161850 rs2295814 rs2850762 rs3750751 rs4240506 rs4749959 
rs2180989 rs2296327 rs2850763 rs3750800 rs4245585 rs4751113 
rs2181891 rs2297291 rs2850764 rs3753579 rs4245586 rs4771436 
rs2188525 rs2298432 rs2854344 rs3761144 rs4252491 rs4823613 
rs2188530 rs2298771 rs2859817 rs3766741 rs4252492 rs483021 
rs221717 rs2304010 rs2887115 rs3768293 rs4252511 rs4838524 
rs2224780 rs2304014 rs2893022 rs3769931 rs4253042 rs484926 
rs2226711 rs2307491 rs2893830 rs3769938 rs4253047 rs4870268 
rs222747 rs231018 rs2976441 rs3769949 rs4253073 rs488133 
rs2227869 rs2335410 rs2978296 rs3774937 rs4253077 rs4902345 
rs2228526 rs2341629 rs2978662 rs3778148 rs4253082 rs4911165 
rs2228528 rs2352262 rs2978663 rs3778156 rs4253101 rs4940573 
rs2228529 rs2361634 rs3002005 rs3779449 rs4253145 rs4940574 
rs2235132 rs2388546 rs3014804 rs3779647 rs4253160 rs4941183 
rs2236058 rs2389098 rs3020729 rs3780014 rs4253219 rs4941185 
rs2236256 rs2393585 rs3025010 rs3782970 rs4253681 rs4941189 
rs2237528 rs2393596 rs3025033 rs3782972 rs4253755 rs4941195 
rs2237529 rs2393599 rs3025035 rs3783240 rs4285028 rs4943046 
rs2238833 rs2393607 rs3025042 rs3788205 rs4303728 rs4948255 
rs2239185 rs2393609 rs3026645 rs3791253 rs43044 rs4948385 
rs224082 rs2393610 rs302673 rs3793784 rs4310443 rs4948393 
rs224083 rs2393612 rs303774 rs3793786 rs4310561 rs4948410 
rs2241113 rs2393613 rs303802 rs3793854 rs4314511 rs4948412 
rs2241538 rs2393623 rs303807 rs3793859 rs4318891 rs496571 
rs4978536 rs6060763 rs6917325 rs7550536 rs8094315 rs994398 
rs498631 rs606148 rs6927269 rs7551761 rs8096380 rs9965844 
rs4986894 rs6087772 rs692995 rs7557805 rs8096471 rs997238 
rs4987585 rs6088655 rs6935207 rs7561953 rs8141815 rs998584 
rs4987599 rs6121038 rs6935927 rs7562525 rs8177139 rs9990 
rs4987613 rs613355 rs6945352 rs7565062 rs8190996 rs17149866 
rs4987661 rs614080 rs6952619 rs7570201 rs833060 rs2188528 
rs4987702 rs619974 rs6965402 rs757228 rs833069 rs10232449 
rs4987721 rs623956 rs6966 rs757343 rs84770 rs1978095 
rs4987724 rs6328 rs6968274 rs7574618 rs854555 rs12704366 
rs4987736 rs6330 rs6975647 rs757847 rs873457 rs17149850 
rs4987746 rs636433 rs6977797 rs758000 rs874742 rs10246878 
rs4987757 rs6432885 rs6980031 rs7582791 rs876430 rs4263684 
rs4987765 rs6432888 rs699946 rs7586412 rs879825 rs7796247 
rs4987768 rs6432916 rs7004754 rs7586794 rs880301 rs2622624 
rs4987778 rs644261 rs7072073 rs7590387 rs899968 rs1800130 
rs4987801 rs6467882 rs7075820 rs7593452 rs905238 rs1610157 
rs4987808 rs6467890 rs7077937 rs7597971 rs910330 rs1800797 
rs4987821 rs6472841 rs7087489 rs7600731 rs913930 rs6765101 
rs4987825 rs6473797 rs7100767 rs7607896 rs917557 rs4253686 
rs4987828 rs6479706 rs714307 rs763448 rs922116 rs4253701 
rs4987835 rs6479711 rs720321 rs764481 rs922224 rs4253652 
rs4987839 rs648007 rs722204 rs764660 rs9289182 rs5769366 
rs4987843 rs6482747 rs7231531 rs766323 rs929416 rs135549 
rs4987851 rs6492706 rs7232625 rs7745499 rs929737 rs4253623 
rs4987852 rs6506676 rs723685 rs7774038 rs9332216 rs8090926 
rs4987869 rs6525485 rs7242402 rs7778344 rs935403 rs10929303 
rs4987873 rs6537539 rs726511 rs7790798 rs9357155 rs1573601 
rs510769 rs6537860 rs727299 rs7794797 rs9371781 rs6060127 
rs511435 rs6599251 rs728539 rs7796947 rs938487 rs6060531 
rs520342 rs660756 rs731014 rs7797314 rs9400393 rs6060563 
rs5277 rs6616813 rs7320009 rs7800456 rs9474321 rs6060652 
rs534561 rs661825 rs7321909 rs7802397 rs947895 rs689466 
rs535372 rs6658541 rs732518 rs7804449 rs9479791 rs6900017 
rs544093 rs6673287 rs732774 rs7805499 rs949037 rs6900677 
rs545238 rs6673867 rs7328751 rs7809256 rs949879 rs6906755 
rs557311 rs668394 rs7334764 rs7818511 rs9516418 rs7530686 
rs557748 rs671531 rs735883 rs782054 rs9535809 rs754512 
rs558948 rs6718242 rs7364220 rs7858741 rs956572 rs754610 
rs563649 rs6722462 rs7373373 rs7885634 rs9586002 rs7548209 
rs569284 rs6732627 rs740649 rs7889824 rs9610470 rs7991232 
rs577306 rs6734499 rs747781 rs7896287 rs9649651 rs8083946 
rs5918757 rs6736291 rs749072 rs7902905 rs9649652 rs8084922 
rs5958324 rs6738638 rs749174 rs7907557 rs967614 rs8088662 
rs5958347 rs6741870 rs752081 rs7907761 rs968340 rs9812515 
rs5980747 rs6744911 rs7521 rs7910123 rs971667 rs9829181 
rs603965 rs6758728 rs7523086 rs7911934 rs9804190 rs9830721 
rs6058381 rs6789471 rs752569 rs7990565 rs9807663 rs9888034 
 
b.  SNPs genotyped by pyrosequencing  
 
rs42342 rs1800668 rs657770 rs11407 rs17139614 rs13402540 
rs42049 rs904775 rs303817 rs2682560 rs545331 rs13007020 
rs11615 rs9936741 rs4764585 rs7597178 rs11707517 rs6756630 
rs238403 rs2976433 rs7976804 rs2233913 rs4280575 rs9646772 
rs5980747 rs11135835 rs10952540 rs3810660 rs4676590 
ATP7A 
c317 
rs1997625 rs600120 rs3025000    
 
 
Supplemental Table 3. Genes in common between DMET 1.0 and the 123 genes assessed in this study 
 
ABCB1 ABCC1 ABCC2 ABCC5 ABCG2 ALDH1A1 ATP7A ATP7B CYP1B1 CYP2C19 CYP2C8 
CYP2C9 CYP2D6 GSTA1 GSTP1 PPARG SLC15A2 SLC19A1 SLC22A1 SLC22A2 TPMT UGT1A1 
XDH           
 
 
 
 
 
 
 
 
 
 
 
 
 
